Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adiposity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    124 result(s) found for: Adiposity. Displaying page 2 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2014-004454-34 Sponsor Protocol Number: NN8022-4181 Start Date*: 2017-09-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double-blind, placebo-controlled trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of liraglutide in obese children aged 7 to 11 years
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000819-16 Sponsor Protocol Number: VICSUB Start Date*: 2006-03-14
    Sponsor Name:HYKS, sisätautien toimiala, diabetesklinikka
    Full Title: RIMONABANT-LÄÄKEHOIDON JA LAIHDUTUKSEN VAIKUTUKSET MAKSAN RASVAPITOISUUTEEN JA RASVAKUDOKSEN AINEENVAIHDUNTAAN METABOLISTA OIREYHTYMÄÄ SAIRASTAVILLA POTILAILLA
    Medical condition: Tutkimukseen osallistuu korkeintaan 20 VICTORIA-tutkimukseen jo osallistuvaa keskivartalolihavaa metabolista oireyhtymää sairastavaa potilasta
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003843-12 Sponsor Protocol Number: PP-CT01 Start Date*: 2017-01-16
    Sponsor Name:PILA PHARMA
    Full Title: A Single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in 24 patients with diabetes me...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003072-31 Sponsor Protocol Number: 2378 Start Date*: 2018-05-15
    Sponsor Name:VU University Medical Center
    Full Title: The effects of sex hormone administration on marrow and visceral adiposity
    Medical condition: Healthy transgender persons (the effect of differences in sex hormones on the amount of bone marrow fat)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023179-25 Sponsor Protocol Number: Start Date*: 2011-09-13
    Sponsor Name:Aintree University Hospital NHS Foundation Trust [...]
    1. Aintree University Hospital NHS Foundation Trust
    2. UNIVERSITY OF LIVERPOOL
    Full Title: Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome
    Medical condition: Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin levels to a single exenatide injection compared with placebo (0.9% sodium chloride) injection.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-000907-13 Sponsor Protocol Number: 2007-24-001 Start Date*: 2007-11-13
    Sponsor Name:MUW, Innere Med III, Abt.für Endokrinologie & Stoffwechsel
    Full Title: The impact of Rimonabant in overweight women with prior gestational diabetes
    Medical condition: Rimonabant has been shown to reduce body weight and improve cardiovascular risk factors and metabolic control. Therefore we investigate in women with previous gestational diabetes and impaired glu...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033307 Overweight LLT
    9.1 10058110 Dyslipidemia LLT
    9.1 10051361 Adipositas LLT
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024414-61 Sponsor Protocol Number: HJT-PEDOB-MET1 Start Date*: 2011-12-21
    Sponsor Name:Hospital de Girona Dr Josep Trueta
    Full Title: Efectos endocrino-metabólicos, sobre la adiposidad visceral y parámetros de riesgo cardiovascular de la administración de metformina en niños prepuberales con obesidad y marcadores de riesgo para e...
    Medical condition: Obesidad Infantil
    Disease: Version SOC Term Classification Code Term Level
    13 10029883 Obesidad PT
    13 10029883 Obesidad LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004366-14 Sponsor Protocol Number: MK-0364 012 Start Date*: 2006-11-13
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: Full title of the trial A Study to Assess the Efficacy and Tolerability of MK-0364 in Maintaining Weight Loss Induced by Diet in Obese Patients Followed by a 1-Year Extension
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017080-41 Sponsor Protocol Number: GWMD09112 Start Date*: 2010-04-19
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease.
    Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020458-33 Sponsor Protocol Number: GWMD1092 Start Date*: 2010-08-05
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003: GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in ...
    Medical condition: Dyslipidaemia in subjects with type 2 diabetes who have failed to achieve satisfactory lipid control with existing therapies.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000851-41 Sponsor Protocol Number: DRI5029 Start Date*: 2004-10-04
    Sponsor Name:Sanofi-Synthelabo AB
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients
    Medical condition: Obesity is becoming a major health problem in western societies. Its prevalence is increasing especially in USA, UK, and Germany. Obesity is responsible for increased morbidity and mortality. The c...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10029883 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-003320-40 Sponsor Protocol Number: EP-003 Start Date*: 2023-03-14
    Sponsor Name:Empros Pharma AB
    Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002544-28 Sponsor Protocol Number: 0364-011 Start Date*: 2007-01-09
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Phase IIb/III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM)
    Medical condition: Obesity in patients with type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004415-37 Sponsor Protocol Number: NN8022-4179 Start Date*: 2015-11-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week dou...
    Medical condition: Obesity (Prader-Willi syndrome)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001540-38 Sponsor Protocol Number: NN9536-4153 Start Date*: 2015-08-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, mul...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002080-88 Sponsor Protocol Number: NA Start Date*: 2005-09-13
    Sponsor Name:Aintree Hospitals NHS Trust and University of Liverpool
    Full Title: A double−blind, placebo−controlled crossover trial to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal
    Medical condition: Obesity defined as BMI > 30 kg /m2
    Disease: Version SOC Term Classification Code Term Level
    10029883
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003426-28 Sponsor Protocol Number: CBXIGT Start Date*: 2007-08-10
    Sponsor Name:University Hospitals Birmingham NHS Trust
    Full Title: Cortisol metabolism and impaired glucose tolerance
    Medical condition: Impared glucose tolerance
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018429 Glucose tolerance impaired LLT
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000762-20 Sponsor Protocol Number: THR-4109-C-302 Start Date*: 2007-09-05
    Sponsor Name:Theracos, Inc.
    Full Title: A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of Galantamine + Sertraline, Galantamine or Sertraline in Obese Subjects
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013100-32 Sponsor Protocol Number: pms.nov.001 Start Date*: 2009-12-01
    Sponsor Name:University of Exeter [...]
    1. University of Exeter
    2. Royal Devon and Exeter NHS Foundation Trust
    Full Title: Does modulating the gut hormones, incretins, modify vascular function, thereby reducing the risk of vascular complications in insulin resistant individuals?
    Medical condition: Obese (BMI equal or greater than 30) individuals at a high risk of diabetes, but without overt cardiovascular disease or taking oral hypoglycaemic, anti-hypetensive or lipid lowering therapies. Pur...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000567-28 Sponsor Protocol Number: TROTA-1 Start Date*: 2007-09-01
    Sponsor Name:Fundació Clínic Recerca Biomédica
    Full Title: Eficacia de tungstato sódico por vía oral a una dosis fija de 200 mg por día sobre la pérdida de peso en pacientes con obesidad grado I y grado II.
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity PT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 20:33:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA